Bridging the Gaps in Lung Cancer: 6 Month Update Winter Lung Cancer Conference 2025 - Episode 5

Shifting Paradigms With Perioperative Treatment Strategies in Early-Stage NSCLC

,

Panelists discuss how recent data from KEYNOTE-671, AEGEAN, and CheckMate 77T reinforce neoadjuvant therapy’s efficacy in early-stage non–small cell lung cancer (NSCLC), showing consistent survival benefits. In contrast, adjuvant data remain conflicting, limiting its role. Neoadjuvant therapy should be prioritized, with adjuvant therapy reserved for select high-risk patients.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Expert Insights on Recent Advancements in LS-SCLC
    EP. 2: Key Updates in the Treatment of ES-SCLC
    EP. 3: Expert Perspectives on Tarlatamab in ES-SCLC
    EP. 4: Looking Ahead in SCLC: ADCs and Other Novel Agents
    Now Viewing
    EP. 5: Shifting Paradigms With Perioperative Treatment Strategies in Early-Stage NSCLC
    EP. 6: Personalizing Adjuvant Targeted Therapy in Early-Stage NSCLC
    EP. 7: New Targeted Approaches in Unresectable Early-Stage NSCL
    EP. 8: Navigating New Treatment Options in the Frontline Management of Advanced EGFR-Mutant NSCLC
    EP. 9: Expert Insights for Treatment Sequencing in EGFR-Mutant Advanced NSCLC in the Second Line and Beyond
    EP. 10: Latest Advances in the Management of Advanced NSCLC with ALK or ROS1 Mutations
    EP. 11: Recent Updates in the Management Advanced NSCLC with HER2 or NRG1 Alterations
    EP. 12: Tailoring Immunotherapy Strategies for Advanced NSCLC

    Video content above is prompted by the following:

    • What are your perspectives on the latest efficacy, safety data, and recent approvals in early-stage NSCLC treatment, and how have these influenced your clinical practice?
    • KEYNOTE-671: Wakelee H, et al. NEJM. 2023;389:491-503. 
    • AEGEAN: Heymach JV, et al. WCLC 2024. Abs OA13.03. (Approval August 2024)
    • CheckMate 77T: Spicer J, et al. ESMO 2024. LBA50(Approval October 2024)
    • Briefly comment on the conflicting data in the adjuvant setting and contrast that with the consistency demonstrated in the neoadjuvant setting, and discuss how you translate this into your clinical practice.
    • Should neoadjuvant therapy be recommended for all patients who do not proceed directly to surgery?
    • In which patients should adjuvant therapy be added, and what is the remaining role for adjuvant therapy alone?
    x